Is Moderna Inc halal to invest in?

As of August 2026, Moderna Inc MRNA.VI is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Moderna Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Moderna Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Moderna Inc?

Muslim investors may consider investing in Moderna Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Moderna Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Moderna Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Moderna Inc updated?

The Shariah compliance status of Moderna Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Moderna Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Moderna Inc?

You can check the latest Shariah compliance status of Moderna Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Moderna Inc MRNA.VI

Last Updated: Aug 10, 12:00 AM·WBAG

MRNA.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Moderna Inc is classified as not halal.

NOT HALAL

Report Source: undefined Quarter Report

Moderna Inc. Stock Analysis MRNA.VI

Austria Health Care Large Cap

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The company is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). The company also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. The company has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).